Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Fel d 1 antibodies for cat-allergic allergic rhinoconjunctivitis during natural home cat exposure
2021-002089-42Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and cat allergy comparing REGN1908 + REGN1909 with Placebo (2 arms). Primary endpoint: Daily combined symptom and medication score. Started Jul 2021; status: completed.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
allergic rhinoconjunctivitis (ARC)cat allergy
Beyond the preview
Go deeper on 2021-002089-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002089-42.